Vireo Q2 Earnings: Revenue Jumps 335% Following M&A Push, but Margins Tell Another Story

Vireo Growth Inc. reported second-quarter 2026 revenue of $209.3 million, up 335% from $48.1 million a year earlier, as a rapid series of acquisitions transformed the size and composition of the cannabis operator.

But the more consequential question for investors may be what happens to profitability as those businesses are integrated.

Vireo’s adjusted EBITDA increased 212% year over year to $41.5 million, while its adjusted EBITDA margin declined to 19.8% from 27.7%. The contrast illustrates the challenge facing a company attempting to consolidate businesses at an unusually rapid pace: Vireo is getting substantially larger, but it still has to demonstrate what the combined platform can earn once the integration work is further along.

The company itself is pointing investors toward that longer-term test.

“We believe the cannabis industry is entering a period where scale alone is no longer enough,” CEO John Mazarakis said in a press release on Tuesday morning. He argued that lasting value will depend on disciplined capital allocation, operational execution and the ability to integrate businesses efficiently.

Vireo’s Q2 Revenue Nearly Doubled Sequentially

The transformation is visible even compared with the previous quarter.

GAAP revenue increased 97.1% from $106.2 million in the first quarter to $209.3 million in Q2. Cannabis revenue accounted for $175.8 million, while Vireo reported $33.5 million of non-cannabis revenue.

That new non-cannabis business reflects Vireo’s expansion beyond its traditional cannabis operations, including the acquisition of Hawthorne Gardening Company and Bridgewell Agribusiness.

On a pro forma basis, Vireo said Q2 revenue would have reached $254.9 million if the Hawthorne, Bridgewell and PharmaCann acquisitions had been completed on April 1.

The distinction matters. Much of the headline growth reflects businesses added through M&A rather than comparable organic growth within Vireo’s historical operations.

Scale Is Growing Faster Than Margins

Vireo generated $95.3 million in GAAP gross profit during Q2, compared with $20.4 million a year earlier. Gross margin improved year over year to 45.5% from 42.4%.

Sequentially, however, the picture looks different.

Gross margin declined from 55.8% in Q1 to 45.5% in Q2. Adjusted gross margin fell from 56.3% to 47.0%.

Adjusted EBITDA increased from $32.7 million to $41.5 million sequentially, but adjusted EBITDA margin declined sharply from 30.8% to 19.8%.

The cannabis business showed a similar pattern. Adjusted cannabis EBITDA increased to $39.4 million from $32.7 million in Q1, while the corresponding margin declined from 30.8% to 22.4%.

That does not necessarily indicate deterioration in the underlying businesses. Vireo changed substantially during the quarter as newly acquired operations entered its financial statements. But it does establish an important benchmark for upcoming quarters: investors can now watch whether integration and procurement efficiencies begin pushing margins back upward.

Vireo Is Building One of Cannabis’ Largest Footprints

Few cannabis companies are currently pursuing consolidation on Vireo’s scale.

During Q2, the company completed its transactions involving Eaze, Hawthorne and Bridgewell. It also announced agreements involving FLUENT and C21 Investments.

The pace continued after June 30.

Vireo subsequently completed its acquisition of certain PharmaCann assets in Colorado and acquired a Pennsylvania dispensary license transaction that can authorize up to six dispensaries, subject to regulatory approvals.

It also announced an agreement to acquire certain Cannabist Company assets, including cultivation, manufacturing and as many as 20 retail operations, expanding Vireo’s footprint into Illinois, Massachusetts and New Jersey.

Vireo separately announced an all-stock merger with Planet 13 Holdings and four Ohio acquisitions that would establish a vertically integrated operation with eight dispensaries plus cultivation and processing assets.

Assuming all announced acquisitions are completed, Vireo said it would operate approximately 270 dispensaries, making it the largest U.S. cannabis operator by dispensary count and placing it among the industry’s largest companies by revenue.

$122.7 Million in Cash — and More Capital Available

Financing this expansion is another part of the equation.

Vireo finished June with $122.7 million in cash and $1 million in marketable securities. Current assets excluding income-tax receivables totaled $374 million, compared with $181.4 million of current liabilities excluding uncertain tax liabilities and contingent consideration.

After quarter-end, Vireo also announced an asset-based revolving credit facility with an initial commitment of $65 million.

The facility can expand to $85 million and includes another $20 million accordion, potentially bringing total capacity to $105 million. Pricing is Term SOFR plus 1.75% to 2.00%.

Importantly, management does not appear to consider the current acquisition cycle finished. Vireo explicitly said it expects to remain acquisitive.

That makes capital allocation increasingly important. The question is no longer simply how many assets Vireo can assemble, but how effectively management can deploy its cash, credit capacity and equity while integrating a rapidly expanding portfolio.

The Next Phase Is About Earnings Power

Mazarakis said Vireo is focused on improving profitability and free cash flow while developing businesses capable of generating more than $100 million across its core markets over time.

Management expects the full earnings power of the platform to become clearer as integration continues into 2027.

That timeline is important.

Q2 provides evidence that Vireo can rapidly assemble scale: revenue has more than quadrupled year over year, its geographic footprint continues to expand, and the company has secured additional liquidity for further transactions.

What Q2 cannot yet demonstrate is what the economics of the finished platform will ultimately look like.

For investors, the next several quarters should begin answering that question. Revenue growth will increasingly need to be evaluated alongside margin recovery, free cash flow, acquisition integration and the returns Vireo generates from the capital it is deploying.

In that sense, Vireo’s Q2 earnings may mark the transition from one phase of its strategy to another. Building scale has become increasingly visible. Turning that scale into durable earnings is now the more important test.